Cancer Research UK and France’s Institut National du Cancer have partnered to fund researchers through the global Cancer Grand Challenges initiative.
With just days left before the end of September, and with it, the end of fiscal year 2023, NCI officials are preparing for rough times, both in the short term and long term.
FDA is accepting applications for its Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01). This program is administered by the FDA’s Office of Orphan Products Development.
Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine to support three novel phase I clinical trials evaluating innovative cell and gene therapy treatments for patients with acute myeloid leukemia and other diseases.
The DeGregorio Family Foundation with the support of the Price Family Foundation and the Esophageal Cancer Awareness Association has awarded $87,500 to Dawit Kidane-Mulat, associate professor at Howard University College of Medicine, to complete his grant focused on improving the effectiveness of immunotherapy in gastric cancers.
The application period for the DKMS John Hansen Research Grant 2024 began Aug. 1.
NCI continues to face the prospect of flat funding in fiscal year 2024 as a spending bill proposes a 3% cut to NCI’s budget, which threatens to further reduce the institute’s purchasing power, said NCI Director Monica Bertagnolli.
The fiscal year 2024 Labor, HHS, Education, and Related Agencies spending bill heading for approval by the House Appropriations Committee cuts NIH by $2.8 billion and NCI by $216 million.
Surgeons who also conduct important biomedical research are struggling to obtain research funding, and that “broken pipeline” could spell extinction for surgeon-scientists and slow innovations for patients, a team of UVA Health experts said.
The White House has awarded NCI $50 million to establish five centers for cancer control research in persistent poverty areas.
